Is MeiraGTx Holdings plc (MGTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 15.1% / 30% | 18.4% / 30% | 1.9% / 30% | 12.46% / 5% | ✗ NOT HALAL |
| DJIM | 15.1% / 33% | 18.4% / 33% | 1.9% / 33% | 12.46% / 5% | ✗ NOT HALAL |
| MSCI | 31.4% / 33% | 38.4% / 33% | 3.9% / 33% | 12.46% / 5% | ✗ NOT HALAL |
| S&P | 15.1% / 33% | 18.4% / 33% | 1.9% / 33% | 12.46% / 5% | ✗ NOT HALAL |
| FTSE | 31.4% / 33% | 38.4% / 33% | 3.9% / 50% | 12.46% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 94.0% | |
| Operating Margin | 35.1% | |
| Net Margin | -140.3% | |
| Return on Equity (ROE) | -368.2% | |
| Return on Assets (ROA) | -25.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$104M |
| Free Cash Flow | -$109M |
| Total Debt | $85M |
| Current Ratio | 0.7 |
| Total Assets | $270M |
Price & Trading
| Last Close | $7.53 |
| 50-Day MA | $7.58 |
| 200-Day MA | $7.85 |
| Avg Volume | 384K |
| Beta | 1.4 |
|
52-Week Range
$4.55
| |
About MeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MeiraGTx Holdings plc (MGTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MeiraGTx Holdings plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MeiraGTx Holdings plc's debt ratio?
MeiraGTx Holdings plc's debt ratio is 15.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 31.4%.
What are MeiraGTx Holdings plc's key financial metrics?
MeiraGTx Holdings plc has a market capitalization of $618M, and revenue of $33M. The company maintains a gross margin of 94.0% and a net margin of -140.3%. Return on equity stands at -368.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.